Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(13%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_2
2
25%
Ph phase_1
3
38%
Ph phase_3
3
38%

Phase Distribution

3

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(6)
Other(1)

Detailed Status

Completed6
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 22 (25.0%)
Phase 33 (37.5%)

Trials by Status

completed675%
active_not_recruiting113%
unknown113%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_2

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

NCT03755804
unknownphase_1

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

NCT02076646
completedphase_3

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

NCT00038558
completedphase_1

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

NCT01056679
completedphase_2

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

NCT01028222
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03755804Phase 2

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active Not Recruiting
NCT02076646Phase 1

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Unknown
NCT00038558Phase 3

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Completed
NCT01056679Phase 1

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

Completed
NCT01028222Phase 2

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Completed
NCT00264953Phase 3

HD11 for Intermediate Stages

Completed
NCT00265018Phase 3

HD10 for Early Stages

Completed
NCT00327600Phase 1

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8